Instagram Co-Founders to Step Down From Facebook 
 

The two co-founders of Facebook's popular Instagram app are stepping down, a surprise move marking continued tumult at the social-networking giant.

 
Google CEO to Meet With Top GOP Lawmakers 
 

Google Chief Executive Sundar Pichai plans to appear at a private meeting of top GOP lawmakers on Friday and again at a public hearing this year, responding to new scrutiny of the company's work with China, its market power and alleged bias in its search results.

 
BNY Mellon to Wind Down Hedge-Fund Investment Unit 
 

The Bank of New York Mellon Corp. plans to close a fund-management subsidiary that invested in various hedge funds, as demand for such investment vehicles wanes.

 
Boeing Wins Air Force Chopper Deal 
 

Boeing secured a Pentagon contract worth up to $2.4 billion to provide helicopters for protecting nuclear-missile bases. The aerospace giant is awaiting the outcome of a larger deal to build Air Force trainer jets.

 
Shell CEO Considers Natural-Gas Bet 
 

Ben van Beurden said a consortium led by the energy giant will decide before year-end whether to proceed with a $30 billion, liquefied-natural-gas export terminal in western Canada.

 
Deutsche Bank's German Regulators Show Impatience With Money-Laundering Controls 
 

Germany's financial watchdog ordered Deutsche Bank to bolster its controls to prevent money laundering in a reprimand that comes amid a growing focus on European lenders' progress policing financial crime.

 
Former Invitation Homes CEO Joins Deutsche Bank 
 

John Bartling, former CEO of Invitation Homes, joined Deutsche Bank as a senior U.S. banker, in a bid by the bank to boost its relationships with corporate boards, private-equity firms and other deal makers.

 
Big Tech's Business Model Is Broken: Report 
 

Silicon Valley tech giants can't be trusted to police themselves and should be subject to tougher regulation, including around their pattern of acquiring competitors to accumulate ever-larger stores of user data, according to a critical new report released Monday.

 
Gilead to Slice List Prices of Liver Drugs 
 

The drugmaker intends to slash the list price of its hepatitis C treatments as it responds to competitive pricing pressures and shifts in the U.S. payment system for pharmaceuticals.

 
Amarin Surges on Fish-Oil Drug Data 
 

Amarin more than tripled in value after the company said its drug derived from fish oil reduced the risk of heart attacks, strokes and deaths in certain high-risk patients.

(END) Dow Jones Newswires

September 24, 2018 23:00 ET (03:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.